Authors: Angela Hewlett, Isabel Ramirez
RECOMMENDATION: No. There are no tests that can be used to guide therapies and monitor responses to treatments in patients with PJIs. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) are considered useful for monitoring responses to treatments; however, sustained elevations after treatment does not predict persistent infections. Emerging biomarkers, such as D-dimer and presepsin, have shown promising results. Nevertheless, more studies are required to assess their role in monitoring response to treatment in patients with PJIs.
LEVEL OF EVIDENCE: Moderate
DELEGATE VOTE: Agree: 89%, Disagree: 8%, Abstain: 3% (Super Majority, Strong Consensus)
